Demonstration of an increase of this cell type in patients dying of COVID-19 points to a potential therapeutic intervention with the drug Fevipiprant, which blocks CD8+ Tc2 cell activation and its pro-fibrotic effects by inhibiting prostaglandin D2 signaling [63]. The gene discussed is CD8A; the disease is COVID-19.